UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent Lg-Ir-Nmibc
URGN•NDA submission for UGN-103
UroGen Pharma Ltd. submitted a New Drug Application (NDA) for UGN-103, an investigational treatment of recurrent LG-IR-NMIBC.
URGN•
